FDA Approval of LEQVIO(R) (inclisiran)
Novartis has announced that LEQVIO® (inclisiran) has been approved by the FDA for patients with atherosclerotic cardiovascular disease (ASCVD) who need to further lower their bad cholesterol, despite being on a maximally tolerated statin. If interested, the LEQVIO full prescribing information can be found here: https://www.novartis.us/sites/www.novartis.us/files/leqvio.pdf Novartis is committed to continuing their work with the…
Read More2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
Read More
Read MoreNew CDC Foundation Campaign Appeals to Americans-Focus On Your Heart Health During the Pandemic
Read the press release
Read MoreBreakthrough results for Jardiance® (empagliflozin) confirm EMPEROR-Preserved as first and only successful trial for heart failure with preserved ejection fraction
Read the Press Release
Read MoreASPC to Partner with Vindico Med Ed on CE Symposium: Saving the Hearts of Women with Prevention
Read the Press Release
Read MoreNovartis Entresto® granted expanded indication in chronic heart failure by FDA
Read the Press Release
Read MoreASPC Officially Announces Erin Michos, MD, MHS, FASPC as Co-Editor-in-Chief of AJPC
Read the Press Release
Read MoreIndustry News: FDA Approves New Drug for the treatment of patients with HoFH
View the Press Release
Read MoreSurgeon General releases a Call to Action on Hypertension
The office of the Surgeon General releases a call to action recommending that hypertension control become a national public health priority, optimizing patient care, and building a community to help control high blood pressure. Progress made in controlling hypertension “is slipping away from us”, said, U.S. Surgeon General Jerome M. Adams, MD, MPH. This leaves…
Read MoreEsperion Launches U.S. Direct-to-Consumer Campaign to Accelerate Awareness of NEXLETOL® (bempedoic acid) Tablets and Increase Awareness of Bad Cholesterol
View the Press Release
Read More